All In Biotech

Investigational drug · Phase 2

Finotonlimab

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

9

Any phase or sponsor naming "Finotonlimab"

First trial start

2025

Jun 24, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Finotonlimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Hepatocellular Carcinoma

Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Finotonlimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 15 on PubMed

Also in development for Advanced Hepatocellular Carcinoma

  • PF-08634404SSGJ-707Phase 312 trials

    Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)

  • pegargiminaseADI-PEG 20Phase 33 trials

    Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.